분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-11-26 10:15:25 , Hit : 2115
 J&J, Medivir Win U.S. FDA Approval for Hepatitis C Pill

By Anna Edney - Nov 23, 2013 2:01 PM GMT+0900 .
.

Facebook Share
Tweet
LinkedIn
Google +1
0 Comments

Print

QUEUE


Q

..




Johnson & Johnson (JNJ) and Medivir AB (MVIRB) won U.S. approval for their pill to treat chronic hepatitis C, the first drug allowed for sale in a competition to bring new treatments for the virus to market.

The Food and Drug Administration cleared simeprevir, to be called Olysio, in combination with other medicines for the viral disease that damages the liver, the agency said in a statement. The drug can shorten current treatment by half, limiting interferon injections that may cause flu-like symptoms.

.

J&J, Medivir, Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) are among companies developing new pills for the virus to alleviate the burden of current therapies. The market for hepatitis C drugs may reach more than $100 billion over a decade, Bloomberg Industries said. Olysio may generate $447 million for New Brunswick, New Jersey-based J&J in 2016, according to the average of four analysts’ estimates compiled by Bloomberg.

“Olysio is the third FDA-approved protease inhibitor to treat chronic hepatitis C virus infection, and provides health professionals and patients with a new, effective treatment for this serious disease,” Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in yesterday’s statement.

Baby Boomers

About 4 million Americans have the disease, which can cause liver cirrhosis, according to the National Institutes of Health. Hepatitis C can be passed through infected blood or body fluids, most commonly through needle-sharing by drug users. The virus may be carried for years without symptoms and the U.S. Centers for Disease Control and Prevention recommended last year that baby boomers, defined by the agency as those born from 1945 to 1965, get tested for the infection.

The medicine from J&J, the world’s biggest seller of health-care products, and Huddinge, Sweden-based Medivir, is for use in combination with pegylated interferon and a pill called ribavirin for those with genotype 1, the most common form of the disease, J&J said in a statement. Interferon and ribavirin make up the backbone of current treatments. Most patients now take the combination with Merck & Co.’s Victrelis or Vertex Pharmaceuticals Inc. (VRTX)’s Incivek for as long as 48 weeks.

Olysio is in a class of drugs that also include Victrelis and Incivek, though patients who used it in clinical trials were treated in just 24 weeks. The experimental hepatitis C pills are designed to be more convenient to take, reduce treatment times and avoid the side effects of current therapies.

Study Data

Clinical studies showed 80 percent of patients given Olysio who had never been treated before no longer had detectable virus in their blood and 79 percent of those who tried other treatments before Olysio were cured as well, the FDA said.

The FDA is supposed to decide by Dec. 8 whether to approve Foster City, California-based Gilead’s sofosbuvir. If cleared for sale, the medicine would be the first all-oral treatment for two forms of hepatitis C that make up as many as 25 percent of patients. Hepatitis C is divided into six genotypes. Genotype 1 patients account for about 70 percent of those in the U.S. who have the disease.

Olysio’s label suggests patients be screened for a genetic mutation called Q80K polymorphism that renders the drug ineffective. In clinical trials the mutation showed up in about 48 percent of U.S. patients with genotype 1a infection, the more common subtype in the U.S. compared with genotype 1b, which is more prevalent in Europe and Asia and isn’t typically associated with the mutation.

Olysio users also are cautioned to limit sun exposure as some clinical trial participants experience serious photosensitivity reactions requiring hospitalization.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net







807   새로운 C형 간염 약들  이성욱 2013/12/09 2263
806   “맞춤형 정자 (Designer Sperm)”, 새로운 유전 혁명!  이성욱 2013/12/09 2160
805   HIV 복제를 차단하는 방법  이성욱 2013/12/06 1966
804   뇌 연결성에 있어 남녀의 현저한 차이  이성욱 2013/12/06 2162
803   점점 더 높아져가는 인간의 육식성향 - 생태계에 드리우는 먹구름  이성욱 2013/12/06 2284
802   과도한 음주에 대한 유전자 돌연변이 발견  이성욱 2013/12/06 2139
801   후손에게 전달되는 공포의 기억  이성욱 2013/12/06 8008
800   사람의 심장에 대한 역행 유전자 요법 기술의 역사적인 첫 번째 시술  이성욱 2013/12/06 2535
799   줄기 세포를 표적으로 대장암 치료의 새로운 길 열려!  이성욱 2013/12/06 2156
798   C형 간염 바이러스의 E2 외피 당단백 구조  이성욱 2013/12/06 2120
797   이제는 유전자 편집 시대: 실험실에서 바이오텍 업체로 넘어간  이성욱 2013/12/06 2455
796   유방암의 cyclin D1과 마이크로 알앤에이의 연관성  이성욱 2013/12/05 2301
795   이성(異性)의 존재가 초파리와 선충류의 수명을 단축  이성욱 2013/12/05 2349
794   유전자조작 옥수수와 실험쥐 종양사이의 연관성을 다룬 논문철회  이성욱 2013/12/02 2342
793   미국 개인 유전체 서비스 시장 동향: 23andME, DNA 검사키트 판매 중단  이성욱 2013/11/28 2684
  J&J, Medivir Win U.S. FDA Approval for Hepatitis C Pill  이성욱 2013/11/26 2115
791   가장 보편적 발암 단백질 저해제와 그 메커니즘  이성욱 2013/11/25 2170
790   Tufts report confirms domination of biotech products  이성욱 2013/11/19 1864
789   뇌 면역세포에서만 발현되는 유전자의 발견  이성욱 2013/11/18 2276
788   인터페론 프리 … C형간염 먹는 약 시대 도래  이성욱 2013/11/15 3211

[이전 10개] [1]..[21][22][23] 24 [25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN